Increased glyceraldehyde-3-phosphate dehydrogenase expression in renal cell carcinoma identified by RNA-based, arbitrarily primed polymerase chain reaction

Cancer

Volumn 89, Issue 1, 2000, Pages 152-164

  Vilà, Maya R ^a   Nicolás, Antoni ^a   Morote, Joan ^b   De Torres, Inés ^c   Meseguer, Anna ^a  

^a Hospitals Universitaris Vall d'H   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c Hospitals Universitaris Vall d'H   (Spain)

Author keywords

GAPDH; Gene expression; Human kidney; Proliferation markers; RAP PCR; Renal call carcinoma

Indexed keywords

FERRITIN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HLA A ANTIGEN; LACTATE DEHYDROGENASE;

ADULT; AGED; AMINO ACID SEQUENCE; ARTICLE; CANCER SCREENING; DIAGNOSTIC VALUE; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY CARCINOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEQUENCE ANALYSIS;

EID: 0034235250     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20000701)89:1<152::AID-CNCR20>3.3.CO;2-K     Document Type: Article

References (57)

1. Robbins AR, Ward RD, Oliver C. A mutation in glyceraldehyde-3-phosphate dehydrogenase alters endocytosis in CHO cells. J Cell Biol 1995;130:1093-104.
2. Sirover MA. Role of the glycolytic protein, glyceraldehyde-3-phosphate dehydrogenase, in normal cell function and in cell pathology. J Cell Biochem 1997;66:133-40.
3. Sawa A, Khan AA, Hester LD, Snyder SH. Glyceraldehyde-3-phosphate dehydrogenase: nuclear translocation participates in neuronal and nonneuronal cell death. Proc Natl Acad Sci USA 1997;94:11669-74.
4. Tanabe K, Campbell SC, Alexander JP, Steinbach F, Edinger MG, Tubbs RR, et al. Molecular regulation of intercellular adhesion molecule 1 (ICAM-1) expression in renal cell carcinoma. Urol Res 1997;25:231-8.
5. Katagiri A, Watanabe R, Tomita Y. E-cadherin expression in renal cell cancer and its significance in metastasis and survival. Br J Cancer 1995;71:376-9.
6. Shimazui T, Bringuier PP, van Berkel H, Ruijter E, Akaza H, Debruyne FM, et al. Decreased expression of alpha-catenin is associated with poor prognosis of patients with localized renal cell carcinoma. Int J Cancer 1997;74:523-8.
7. Yoshida MA, Ohyashiki K, Ochi H, Gibas Z, Prout GRJ, Pontes JE, et al. Rearrangement of chromosome 3 in renal cell carcinoma. Cancer Genet Cytogenet 1986;19:351-4.
8. Wilhem V, Bugert P, Kenck C, Staehler G, Kovacs G. Terminal deletion of chromosome 3p sequences in nonpapillary renal cell carcinomas: a breakpoint cluster between loci D3S1285 and D3S1603. Cancer Res 1995;55:5383-5.
9. Druck T, Kastury K, Hadaczek P, Podolski J, Toloczko A, Sikorski A, et al. Loss of heterozygosity at the familial RDD t(3;8) locus in most clear cell renal carcinomas. Cancer Res 1995;55:5348-53.
10. Thrash-Bingham C, Salazar H, Freed J, Greenbert R, Tartof K. Genomic alterations and instabilities in renal cell carcinomas and their relationship to tumor pathology. Cancer Res 1995;55:6189-95.
11. Uchida T, Wada C, Shitara T, Egawa S, Mashimo S, Koshiba K. Infrequent involvement of p53 mutations and loss of heterozygosity of 17p in the tumorigenesis of renal cell carcinoma. J Urol 1996;150:1298-301.
12. Rochlitz CF, Peter S, Willroth G, de Kant F, Lobeck H, Huhn D, et al. Mutations in the ras proto-oncogenes are rare events in renal cell cancer. Eur J Cancer 1992;28:333-6.
13. Chandler D, El-Naggar AK, Brisbay S, Redline RW, McDonnell TJ. Apoptosis and expression of the bcl-2 proto-oncogene in the fetal and adult human kidney: evidence for the contribution of bcl-2 expression to renal carcinogenesis. Hum Pathol 1994;25:789-96.
14. Yao M, Shuin T, Misaki H, Kubota Y. Enhanced expression of c-myc and epidermal growth factor receptor (C-erbB-1) genes in primary human renal cancer. Cancer Res 1988;48: 6753-7.
15. Freeman MR, Washecka R, Chung LWK. Aberrant expression of epidermal growth factor receptor and HER-2 (erbB-2) messenger RNAs in human renal cancers. Cancer Res 1989;49:6221-5.
16. Mydlo JH, Michaeli J, Cordón-Cardó C, Goldenberg AS, Heston WDW, Fair WR. Expression of transforming growth factor α and epidermal growth factor receptor messenger RNA in neoplastic and nonneoplastic human kidney tissue. Cancer Res 1989;49:3407-11.
17. Meliá MJ, Bofill N, Hubank M, Meseguer A. Identification of androgen-regulated genes in mouse kidney by representational difference analysis and random arbitrarily primed polymerase chain reaction. Endocrinology 1998; 139:688-95.
18. Sancho E, Vilà MR, Sánchez-Pulido L, Lozano JJ, Paciucci R, Nadal M, et al. Role of UEV-1, an inactive variant of the E2 ubiquitin-conjugating enzymes, in in vitro differentiation and cell cycle behavior of HT-29 M6 intestinal mucosecretory cells. Mol Cell Biol 1998;18:576-89.
19. Asadi FK, Dimaculangan DD, Berger FG. Androgen regulation of gene expression in primary epithelial cells of the mouse kidney. Endocrinology 1994;134:1179-87.
20. Chomczynski P, Sacchi N. Single-step method for RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-9.
21. Welsh J, Chada K, Dalal SS, Cheng R, Ralph D, McClelland M. Arbitrarily primed PCR fingerprinting of RNA. Nucleic Acid Res 1992;20:4965-70.
22. Perucho M, Welsh J, Peinado MA, Ionov Y, McClelland M. Fingerprinting of DNA and RNA by arbitrarily primed polymerase chain reaction: applications in cancer research. Methods Enzymol 1995;254:275-90.
23. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment search tool. J Mol Biol 1990;215:403-10.
24. Arenaz P, Sirover MA. Isolation and characterization of monoclonal antibodies directed against the DNA repair enzyme uracil DNA glycosylase from human placenta. Proc Natl Acad Sci USA 1983;80:5822-6.
25. Blin N, Stafford DW. A general method for isolation of high molecular weight DNA from eukaryotes. Nucleic Acids Res 1976;3:2303-8.
26. Shim H, Dolde C, Lewis BC, Wu C-S, Dang G, Jungmann RA, et al. c-myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc Natl Acad Sci USA 1997; 94:6658-63.
27. Pringault E, Arpin M, Garcí a A, Finidori J, Louvard D. A human villin cDNA clone to investigate the differentiation of intestinal and kidney cells in vivo and in culture. EMBO J 1986;5:3119-24.
28. Bhatia P, Taylor WR, Greenberg AH, Wright JA. Comparison of glyceraldehyde-3-phosphate dehydrogenase and 28S-ribosomal RNA gene expression as RNA loading controls for Northern blot analysis of cell lines of varying malignant potential. Anal Biochem 1994;216:223-6.
29. Ishitani R, Sunaga K, Hirano A, Saunders P, Katsube N, Chuang DM. Evidence that glyceraldehyde-3-phosphate dehydrogenase is involved in age-induced apoptosis in mature cerebellar neurons in culture. J Neurochem 1996;66:928-35.
30. Matrisian LM, Rautmann G, Magun BE, Breathnach R, Epidermal growth factor or serum stimulation of rat fibroblasts induces an elevation in mRNA levels for lactate dehydrogenase and other glycolytic enzymes. Nucleic Acids Res 1985; 13:711-25.
31. Schek N, Hall BL, Finn OJ. Increased glyceraldehyde-3-phosphate dehydrogenase gene expression in human pancreatic adenocarcinoma. Cancer Res 1988;48:6354-9.
32. Tokunaga K, Nakamura Y, Sakata K, Fujimori K, Ohkubo M, Sawada K, et al. Enhanced expression of a glyceraldehyde-3-phosphate dehydrogenase gene in human lung cancers. Cancer Res 1987;47:5616-9.
33. Gong Y, Cui L, Minuk GY. Comparison of glyceraldehyde-3-phosphate dehydrogenase and 28S-ribosomal RNA gene expression in human hepatocellular carcinoma. Hepatology 1996;23:734-7.
34. Kim JW, Kim SJ, Han SM, Paik SY, Hur SY, Kim YW, et al. Increased glyceraldehyde-3-phosphate dehydrogenase gene expression in human cervical cancers. Gynecol Oncol 1998; 71:266-9.
35. Malhotra P, Sidhu LS, Singh SP. Serum lactate dehydrogenase level in various malignancies. Neoplasma 1986;33:641-7.
36. Warburg O. On the origin of cancer cells. Science 1956;123: 309-14.
37. Nagy E, Rigby WFC. Glyceraldehyde-3-phosphate dehydrogenase selectively binds AU-rich RNA in the NAD-binding region (Rossmann fold). J Biol Chem 1995;270:2755-63.
38. Hentze MW. Enzymes as RNA-binding proteins: a role for (di)nucleotide-binding domains? Trends Biochem Sci 1994; 19:101-3.
39. Hubank M, Schatz DG. Identifying differences in mRNA expression by representational difference analysis of cDNA. Nucleic Acids Res 1994;22:5640-8.
40. Persons DA, Schek N, Hall BL, Finn OJ. Increased expression of glycolysis-associated genes in oncogene-transformed and growth-accelerated states. Mol Carcinog 1989;2:88-94.
41. Aithal HN, Toback G, Cryst C. Enhancement of renal medullary pyruvate kinase activity during cell proliferation induced by potassium depletion. Am J Physiol 1980;238:E377-83.
42. Cool BL, Sirover MA. Immunocytochemical localization of the base excision repair enzyme uracil DNA glycosylase in quiescent and proliferating normal human cells. Cancer Res 1989;49:3029-36.
43. Mansur NR, Meyer-Siegler K, Wurzer JC, Sirover MA. Cell cycle regulation of the glyceraldehyde-3-phosphate dehydrogenase/uracil DNA glycosylase gene in normal human cells. Nucleic Acids Res 1993;21:993-8.
44. Epner DE, Partin AW, Schalken JA, Isaacs JT, Coffey DS. Association of glyceraldehyde-3-phosphate dehydrogenase expression with cell motility and metastatic potential of rat prostatic adenocarcinoma. Cancer Res 1993;53:1995-7.
45. Engel M, Seifert M, Theisinger B, Seyfert U, Welter C. Glyceraldehyde-3-phosphate dehydrogenase and Nm23-H1/nucleoside diphosphate kinase A. J Biol Chem 1998;273:20058-65.
46. Buszello H, Ackermann R. Immunohistochemical studies on the expression of HLA class I antigen in renal cell carcinoma: comparison of primary and metastatic tumor tissue. Eur Urol 1994;25:158-63
47. Luboldt HJ, Kubens BS, Rubben H, Grosse-Wilde H. Selective loss of human leukocyte antigen class I allele expression in advanced renal cell carcinoma. Cancer Res 1996;56:826-30.
48. Heinemann D, Smith PJ, Symes MO. Expression of histocompatibility antigens and characterization of mononuclear cell infiltrates in human renal cell carcinomas. Br J Cancer 1987;56:433-7.
49. Gastl G, Ebert T, Finstad CL, Sheinfeld J, Gomahr A, Aulitzky W, et al. Major histocompatibility complex class I and class II expression in renal cell carcinoma and modulation by interferon gamma. J Urol 1996;155:361-7.
50. Angus R, Collins CMP, Symes MO. Expression of major histocompatibility complex (MHC) antigens and their loss on culture in renal carcinoma. Eur J Cancer 1993;29A:2158-60.
51. Seliger B, Höhne A, Knuth A, Bernhard H, Meyer T, Tampe R, et al. Analysis of the major histocompatibility complex class I antigen presentation machinery in normal and malignant renal cells: evidence for deficiencies associated with transformation and progression. Cancer Res 1996;56:1756-60.
52. Fleming S. Immunocytochemical localization of ferritin in the kidney and renal tumors. Eur Urol 1987;13:407-11.
53. Esen A, Ozen H, Ayhan A, Ergen A, Tasar C, Remzi F. Serum ferritin: a tumor marker for renal cell carcinoma. J Urol 1991;145:1134-7.
54. Yu DS, Yueh KC, Chang SY, Yang TH, Ma CP. The expression of ferritin on renal cancers and its relationship with cellular differentiation and tumor stage. Br J Urol 1995;75:733-5.
55. Partin AW, Criley SR, Steiner MS, Hsieh K, Simons JW, Lumadue J, et al. Serum ferritin as a clinical marker for renal cell carcinoma: influence of tumor volume. Urology 1995; 45:211-7.
56. Özen H, Uygur C, Sahin A, Tekgül S, Ergen A, Remzi D. Clinical significance of serum ferritin in patients with renal cell carcinoma. Urology 1995;46:494-8.
57. Kirkali Z, Esen AA, Kirkali G, Güner G. Ferritin: a tumor marker expressed by renal cell carcinoma. Eur Urol 1995;28: 131-4.